secwatch.observer — SEC 8-K summary
======================================

Issuer:     GT Biopharma, Inc. (GTBP)
CIK:        0000109657
Form:       8-K
Filed at:   2026-09-25T20:10:15+00:00
Accession:  0001493152-26-044309
Event type: regulatory
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

GT Biopharma regains Nasdaq $1.00 minimum bid price compliance as of September 22, 2026
--------------------------------------------------------------------------------

- Nasdaq notified GT Biopharma on September 22, 2026 that it regained compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).
- Common stock (GTBP) closed above $1.00 per share for at least ten consecutive business days, satisfying Nasdaq's standard for regaining compliance.
- Deficiency began with a November 20, 2025 Nasdaq staff letter citing 30 consecutive business days below $1.00; Nasdaq granted a 180-day extension on May 20, 2026 running to November 16, 2026.
- The notice removes the pending delisting risk that had been outstanding for roughly ten months; no capital raise, reverse split, or other remedial transaction is disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/109657/000149315226044309/0001493152-26-044309-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/109657/000149315226044309/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-044309

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer